Rationale to use Gliovac/ERC1671

Patients suffering from glioblastoma multiforme (GBM) have an extremely poor prognosis. GBM is the most malignant glioma with the median overall survival being 14 months from diagnosis when treated with standard radio and chemotherapy care in EU [endif]--(Stupp et al. 2005; Stupp et al. 2010). When relapsing, according the size of the tumour, KPS, and tumour localisation, statistics suggest that death is imminent between 1 to 4.5 months (95% IC) [endif]--(Park et al. 2010). In the USA, bevacizumab is administered as a second line of treatment (Chamberlain 2011), but it is currently not approved by the EU authorities with its efficiency still being discussed.
The therapeutic vaccine Gliovac/ERC1671 has shown efficacy and immune responses in the tumour-bearing host, manifested by tumour reduction as visible on MRI scans.

The scientific staff

Action mechanism of Gliovac/ERC1671

Indeed, tumour cells express specific surface antigens. These antigens are not produced by healthy cells but are specific to tumour cells and are common between patients with the same tumour type.
By using non-proliferative cancer cell transplantation, it is not just one cancer-related antigen, but a whole set of tumour antigens associated to the glioblastoma, that is inoculated.
By using three different donors, the set of TAA is even broader. Injection of the autologous vaccine preparation will amplify the response of immune cells targeting the TAA present in the patient that is treated.
Upon activation, effector lymphocytes of the immune system are able to identify non-self tumour antigens and destroy the cancer cells that carry these antigens. The immune cells will proliferate and ensure the surveillance within the body, the cancer cells detection, their destruction and eventually patient recovery and immune resistance against the tumor.
Gliovac/ERC1671 is an advanced immunotherapy based on transplantation of tumour cells and lysates in order to stimulate immunity to reject cancer cells [endif]--(Stathopoulos et al. 2008; Stathopoulos A 2012b, 2012a, Bota et al., 2015; Schijns et al., 2015). Gliovac/ERC1671 is a cancer treatment composed of a combination treatment consisting of autologous glioma tumor cells, and allogeneic glioma tumour cells, generated from three different glioma donor cancer patients, and the lysates of all of these cells. Upon intradermal administration of glioma cancer treatment Gliovac/ERC1671, the mixture of the autologous and allogeneic vaccine (cells and lysates) stimulates the immune system to mount an immune response against glioma tumour-associated antigens, which leads to the destruction of glioma tumour cells.
Read more

Visible results after 4 weeks of vaccination

The patient shows continuous regression of clinical symptoms, robust immune response, leading to a beneficial inflammation around the tumor bed and no viable tumor. The patient survived for another 7 months (a total of 15 months after relapse)
Gliovac before treatmentBefore
Gliovac after 4 weeksAfter 3 cycles


If you are willing to help other GBM patients during the clinical development phases, you may provide tumour as raw material for the production of Gliovac/ERC1671. Gliovac/ERC1671 is manufactured using patients’ glioma tumour tissue. ERC has set up a tissue bank to collect tissue in compliance with European Regulatory Affairs. The tissue bank provides you all the required documents, kits for shipment of tissue and ERC will manage all the shipment.
If you are interested, please contact us and we will provide you with a transport kit and instructions for the patient and the treating physician according to EU regulation for tissue donation to the TTB-NL.


The Gliovac/ERC1671 approach is a cell-based therapy recognised by Health Authorities as an ATMP (Advance Therapeutic Medicinal product) by the Committee for Advanced Therapies at the EMA (Record reference: EMA/CAT/324279/2012). Gliovac/ERC1671 has been granted an Orphan drug designation by the Committee for Orphan Medicinal Products at the EMA in November 2013 (Record reference: EU 3/13/1211) and by FDA (12/01/2011).
ERC has reported success in the development of a therapeutic immune responses in glioblastoma tumour patients, manifested by tumour reduction. Primary results on patients at the advance stage of their illness show that the Gliovac/ERC1671 therapy can be protective in early and advanced malignant glioma and is able to break anti-tumour immune tolerance. The approach has been also successfully tested and described in a feasibility first-in-man study. [Bota et al., 2015, Schijns et al., 2015]. 
The safety, and preliminary efficacy results of the “first-in-man” studies were so encouraging that US Health authorities (Food and Drug Administration - FDA) allowed directly a phase II study (NCT01903330).
This double blinded, randomised, two-arm phase II study is performed at the University of California Irvine, currently updating to add the two clinical centres, including of Dana Faber Cancer centre (Boston) and the University of Southern California. This study compares the standard treatment for recurrent glioma in the USA with the product ERC1671 (Gliovac/ERC1671) in 86 patients, and is currently recruiting patients.
The scientific approach of ERC is  supported by confirming letters of eminent Professors from Pittsburg University, John Hopkins Cancer Center and Harvard who are well experienced in the field of glioma tumour therapies.
Recently, the ERC has been granted of a “Seal of Excellence” certificate by the European Commission in a highly competitive evaluation process.
Eventually Gliovac/ERC1671 may not only complement, but even replace existing treatments post surgery and become (part of) the standard treatment. Also, our initial indication is glioma, but it is very likely that the patented concept of the Gliovac/ERC1671 approach can be further utilised for the treatment of other solid tumours, which are surgically treated.
Read more


In order to create an off-the-self source of allogeneic vaccine for inoperable brain tumours, ERC has also obtained a worldwide exclusive license to GBM6 from the University of Minnesota. GBM6 is a glioblastoma stem cell line, with a successfully completed Phase I clinical study in Minnesota. The company plans to move ahead with a phase II clinical study of GBM6 for both inoperable glioblastoma as well as for paediatric pontine glioma (DIPG, diffuse infiltration pontine glioma).